Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition). William Gregory

Cobert's Manual Of Drug Safety And Pharmacovigilance (Third Edition) - William Gregory


Скачать книгу
Chapter 25Post-marketing Spontaneous ICSR/SAE Reporting

       General Principles

       Post-marketing ICSRs versus Clinical Trial ICSRs

       Sources of AEs

       Literature and Publications

       Other Sources of Reports

       Follow-Up

       Notes on United States Requirements for Post-marketing NDA Reporting of SAEs

       MedWatch to Manufacturer Program

       Reports from the FDA via the Freedom of Information Act

       Instructions on Filling Out the MedWatch Form

       European Union Regulations

       General Comments

       Frequently Asked Questions

       Chapter 26Periodic Adverse Drug Experience Reports, and Periodic Safety Update Reports/Periodic Benefit Risk Evaluation Reports

       Introduction

       NDA Periodic Reports

       PSURs to the FDA

       Post-marketing Periodic Reports

       Section 1: Narrative Summary and Analysis

       Section 2: Narrative Discussion of Actions Taken

       Section 3: Index Line Listing

       Section 4: ICSRs

       Other Reports

       Periodic Safety Update Reports

       PSUR in ICH E2C(R2) Format: The Periodic Benefit–Risk Evaluation Report

       Frequently Asked Question

       Chapter 27Signals and Signaling in the Context of Risk Management

       The Signal — Definition

       Signal Sources and Generation

       Increased Frequency

       Data Mining

       Other Sources of Signal Data

       Putting It All Together

       Organizational Team

       Signal Workup

       Prioritize

       Arrange and Review

       The Workup

       The Conclusions and Next Steps

       The Safety Committee

       Computerized Tools for Signal Detection and Workup

       Key Documents on Signaling and Good PV Practices

       FDA Guidance on Good Pharmacovigilance Practices of 3/2005

       Investigating a Signal

       Interpreting a Signal

       EU GVP Module IX — Signal Management (2012: Revision 1, Delivered Nov 2017)

       Frequently Asked Questions

       Chapter 28Risk: What Is It? Risk Management and Assessment, Risk Evaluation and Mitigation Strategies, and Risk Management Plans

       Introduction

       Why Risk Management?

       The US FDA

       The Proposed REMS

       The Approved REMS

       Roles of Key REMS Participants

       Скачать книгу